



MEDICATION ORDERS

NUCALA (MEPOLIZUMAB)

Page 1 of 2

PATIENT INFORMATION	
Name:	DOB:
Allergies:	Date of Referral:

REFERRAL STATUS		
<input type="checkbox"/> New Referral	<input type="checkbox"/> Dose or Frequency	<input type="checkbox"/> Change Order Renewal

DIAGNOSIS AND ICD 10 CODE	
<input type="checkbox"/> Severe Uncontrolled Asthma with Eosinophilic Phenotype ICD 10 Code: J45.50 → Does the patient have current blood eosinophil counts ≥ 150 cells/ μ L? <input type="checkbox"/> YES <input type="checkbox"/> NO	
<input type="checkbox"/> Eosinophilic Granulomatosis with Polyangitis (EGPA) ICD 10 Code: M30.1 → Has the patient relapsed or been refractory to standard of care therapy, including oral steroids? <input type="checkbox"/> YES <input type="checkbox"/> NO	

REQUIRED DOCUMENTATION/TESTING	
<input type="checkbox"/> This signed order form by the provider <input type="checkbox"/> Patient demographics AND insurance information <input type="checkbox"/> Pulmonary Function Tests (if asthma)	<input type="checkbox"/> Clinical/Progress notes, including H&P <input type="checkbox"/> Labs and Tests supporting primary diagnosis including blood eosinophil counts
List Tried & Failed Therapies, including duration of treatment: 1) 2)	

MEDICATION ORDERS	
Dosing for Severe Asthma with Eosinophilic Phenotype	<input type="checkbox"/> Nucala 100mg subQ every 4 weeks
Dosing for EGPA	<input type="checkbox"/> Nucala 300mg subQ every 4 weeks
Refills: <input type="checkbox"/> x 6 months <input type="checkbox"/> x 1 year <input type="checkbox"/> _____ doses	
Treatment Labs: <input checked="" type="checkbox"/> Pregnancy test within 72 hours prior to initiation of therapy for female patient under 55 years of age and no history of surgical hysterectomy.	
<ul style="list-style-type: none">• New orders and progress notes required at least once yearly. A medication substitution may be required based on insurance payer policy due to preferred versus non-preferred medications or based on payer step therapy guidelines.• Please note for patients receiving treatment at the Montgomery Cancer Center: if an infusion reaction occurs, the Montgomery Cancer Center provider will order appropriate rescue medications as deemed medically necessary. This may also include pausing, reducing the rate of infusion or discontinuing the medication.• Please note for patient receiving treatment at Baptist East Outpatient Infusion: if an infusion reaction occurs, the Baptist East staff will follow the PRN hypersensitivity standing orders and will contact the referring provider in the event of an emergency. For life threatening anaphylaxis, Baptist East staff will follow rapid response policy or 911 facility policy.	

Physician Signature:	Date:
----------------------	-------

Patient Name: _____

Patient Date of Birth: _____



MEDICATION ORDERS

NUCALA (MEPOLIZUMAB)

Page 2 of 2

All order sets will include a statement to activate these PRN hypersensitivity standing orders when necessary.

REACTION SYMPTOMS		DRUG	DOSE	ROUTE
Fever, chills and or rigors	✓	Acetaminophen (Tylenol)	1000mg	PO
Itching, facial flushing, hives, rash	✓	Diphenhydramine (Benadryl)	50mg	IVP
	✓	Famotidine (Pepcid)	20mg	IVP
	✓	Methylprednisolone (Solu-Medrol)	125mg	IVP
Hypotension, wheezing, shortness of breath, facial/lip/tongue swelling	✓	Normal Saline	150ml/hr	IV
	✓	Diphenhydramine (Benadryl)	50mg	IVP
	✓	Methylprednisolone (Solu-Medrol)	125ng	IVP
	✓	Hydrocortisone (Solu-Cortef)	50mg	IVP
	✓	Epinephrine Pen	0.3mg	IM
Nausea/Vomiting	✓	Granisetron (Kytril)	1mg	IVP

PROVIDER INFORMATION			
Office Contact Name:			
Prescribing Providers Name:		Provider NPI:	
Office Address:	City:	State:	Zip:
Office Phone Number:		Office Fax Number:	
Physician Signature:		Date:	

For questions, please contact
Baptist Outpatient Infusion Services @ (334) 747-7401

Fax completed form and all documentation to
Baptist Outpatient Infusion Services @ (334) 747-7403